Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abaloparatide to Mitigate Distal Femoral Bone Loss Following Total Knee Arthroplasty
NCT04167163Phase 4Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Jan 2020
- Primary completion
- Apr 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of abaloparatide in osteoporosis (2 arms), sponsored by University of Wisconsin–Madison. Primary endpoint: Change in Distal Femoral Bone Mineral Density at the 25% Regions of Interest at 18 months. Started Jan 2020; status: completed.
02
Drugs
abaloparatide
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT04167163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04167163.